FDA grants ODD to Tempest’s hepatocellular carcinoma treatment
The FDA has granted ODD to Tempest's amezalpat (TPST-1120), for individuals with hepatocellular carcinoma (HCC).
The FDA has granted ODD to Tempest's amezalpat (TPST-1120), for individuals with hepatocellular carcinoma (HCC).
What's Your Reaction?
